KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Amortization (2016 - 2025)

Historic Amortization for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $2.8 billion.

  • Astrazeneca's Amortization rose 8526.67% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.5 billion, marking a year-over-year increase of 2690.77%. This contributed to the annual value of $85.4 billion for FY2025, which is 913.33% up from last year.
  • As of Q4 2025, Astrazeneca's Amortization stood at $2.8 billion, which was up 8526.67% from $84.5 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Amortization peaked at $84.5 billion during Q3 2025, and registered a low of -$746.0 million during Q4 2021.
  • In the last 5 years, Astrazeneca's Amortization had a median value of $4.5 billion in 2022 and averaged $33.0 billion.
  • The largest annual percentage gain for Astrazeneca's Amortization in the last 5 years was 470988.02% (2021), contrasted with its biggest fall of 15028.7% (2021).
  • Over the past 5 years, Astrazeneca's Amortization (Quarter) stood at -$746.0 million in 2021, then soared by 329.62% to $1.7 billion in 2022, then increased by 3.91% to $1.8 billion in 2023, then dropped by 15.73% to $1.5 billion in 2024, then soared by 85.27% to $2.8 billion in 2025.
  • Its Amortization was $2.8 billion in Q4 2025, compared to $84.5 billion in Q3 2025 and $3.6 billion in Q2 2025.